Dr Reddys Laboratories Ltd (RDY) Stock Forecast Nov. 12, 2026
Analysis updated on Nov. 12, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Dr Reddys Laboratories Ltd (RDY) stock forecast summary
Our AI scores Dr Reddys Laboratories Ltd every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Dr Reddys Laboratories Ltd is a large-cap company with a market capitalization of $12.39B. It ranks number 31 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For RDY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 358 forecast dates between 2022-08-25 and 2026-08-14 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -2.0%, measured on 400 forecast dates between 2022-08-25 and 2026-10-13. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.2%, buy ≥ +1.6%, sell < -0.4%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-11 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RDY included.
RDY price chart and AI forecast
How RDY ranks among 4226 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Dr Reddys Laboratories Ltd (RDY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in INR and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | RDY | Rank |
|---|---|---|
| Market Cap | $12.39B | 31/60 |
| P/E Ratio | 16.30x | 22/32 |
| EPS | $0.91 | – |
| Revenue/Share | $4.74 | – |
| FCF/Share | $0.28 | – |
Profitability & Margins
| Metric | RDY | Rank |
|---|---|---|
| Gross Margin | 58.4% | 30/35 |
| Operating Margin | 22.0% | 10/39 |
| EBT Margin | 23.6% | 11/46 |
| Tax Rate | 25.4% | – |
Cash Flow
| Metric | RDY | Rank |
|---|---|---|
| Operating Cash Flow | $569M | 27/60 |
| Free Cash Flow | $237M | 24/51 |
| Capital Spending | -$332M | 34/51 |
| FCF Growth YoY | 0.0% | 15/32 |
| FCF/Sales | 6.0% | 30/42 |
| CapEx/Sales | 8.4% | 6/42 |
Income Statement
| Metric | RDY | Rank |
|---|---|---|
| Total Revenue | $3.96B | 20/46 |
| Operating Income | $872M | 17/52 |
| R&D Expense | $333M | 38/59 |
| SG&A Expense | $1.14B | 22/41 |
| Cost of Goods Sold | $1.65B | 20/36 |
Dividend & Shareholder Information
| Metric | RDY | Rank |
|---|---|---|
| Shares Outstanding | 835M | – |
Balance Sheet Highlights (USD millions, converted from INR)
| Total Liabilities | $1.82B |
RDY quarterly financials and insider trading
Dr Reddys Laboratories Ltd (RDY) industry peers
Companies classified under the same SEC industry code as Dr Reddys Laboratories Ltd (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RDY Dr Reddys Laboratories Ltd | $12.39B | |
| LLY Eli Lilly & Co | $1.35T | |
| JNJ Johnson & Johnson | $675.03B | |
| ABBV Abbvie Inc. | $521.26B | |
| MRK Merck & Co., Inc. | $363.12B | |
| NVS Novartis Ag | $305.91B | |
| AZN Astrazeneca Plc | $287.49B | |
| ABT Abbott Laboratories | $190.04B | |
| NVO Novo Nordisk A S | $182.60B | |
| PFE Pfizer Inc | $167.86B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $138.65B | |
| BMY Bristol Myers Squibb Co | $128.59B | |
| SNY Sanofi | $119.40B | |
| GSK Gsk Plc | $102.08B | |
| REGN Regeneron Pharmaceuticals, Inc. | $98.78B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.10B | |
| TEVA Teva Pharmaceutical Industries Ltd | $50.39B | |
| ONC Beone Medicines Ltd. | $47.74B | |
| GMAB Genmab A/S | $34.66B | |
| ZTS Zoetis Inc. | $34.12B | |
| ROIV Roivant Sciences Ltd. | $30.23B | |
| RPRX Royalty Pharma Plc | $29.98B | |
| INSM Insmed Inc | $26.49B | |
| UTHR United Therapeutics Corp | $25.55B | |
| VTRS Viatris Inc | $24.19B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.41B | |
| ASND Ascendis Pharma A/S | $17.03B | |
| JAZZ Jazz Pharmaceuticals Plc | $16.11B | |
| BBIO Bridgebio Pharma, Inc. | $15.49B | |
| SMMT Summit Therapeutics Inc. | $13.27B | |
| ELAN Elanco Animal Health Inc | $13.23B | |
| BMRN Biomarin Pharmaceutical Inc | $11.29B | |
| TGTX Tg Therapeutics, Inc. | $10.43B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $10.00B | |
| PRAX Praxis Precision Medicines, Inc. | $9.67B | |
| SYRE Spyre Therapeutics, Inc. | $9.42B | |
| PTGX Protagonist Therapeutics, Inc | $8.73B | |
| CYTK Cytokinetics Inc | $8.14B | |
| CORT Corcept Therapeutics Inc | $8.06B | |
| ALKS Alkermes Plc. | $8.03B | |
| AXSM Axsome Therapeutics, Inc. | $7.82B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.72B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.52B | |
| ABVX Abivax S.A. | $7.18B | |
| ORKA Oruka Therapeutics, Inc. | $7.10B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.97B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.93B | |
| MANE Veradermics, Inc | $6.54B | |
| LGND Ligand Pharmaceuticals Inc | $6.34B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.14B | |
| BLTE Belite Bio, Inc | $6.13B | |
| ERAS Erasca, Inc. | $5.88B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| PTCT Ptc Therapeutics, Inc. | $5.42B | |
| EWTX Edgewise Therapeutics, Inc. | $5.17B | |
| COGT Cogent Biosciences, Inc. | $5.10B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.99B | |
| LQDA Liquidia Corp | $4.94B | |
| IONS Ionis Pharmaceuticals Inc | $4.71B | |
| TVTX Travere Therapeutics, Inc. | $4.66B |
Where RDY sits on the market map
Dr Reddys Laboratories Ltd (RDY) stock news
Loading...
Dr Reddys Laboratories Ltd (RDY) stock forecast FAQ
What is the Dr Reddys Laboratories Ltd (RDY) stock forecast?
Our AI scores Dr Reddys Laboratories Ltd every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Dr Reddys Laboratories Ltd stock predictions?
For RDY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 358 forecast dates between 2022-08-25 and 2026-08-14 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -2.0%, measured on 400 forecast dates between 2022-08-25 and 2026-10-13. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Dr Reddys Laboratories Ltd forecasts updated?
Dr Reddys Laboratories Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 12, 2026.
Which companies are Dr Reddys Laboratories Ltd's industry peers?
60 issuers in our coverage, RDY included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.